Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. News
  7. Summary
    QGEN   NL0012169213


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN N.V.: Release of a capital market information

10/12/2021 | 08:16am EST

DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Buyback QIAGEN N.V.: Release of a capital market information 2021-10-12 / 14:15 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.


Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting

With disclosure dated September 22, 2021, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the beginning of a second tranche of up to USD 19.4 million starting on September 27, 2021 under the share repurchase program originally announced on July 12, 2021.

The number of shares which have been bought back within the framework of such tranche of the share repurchase program in the time period from October 4, 2021 until and including October 8, 2021, amounts to 146,926 shares.

Shares were bought back as follows:

      Date        Number of Shares acquired Average Price (EUR) Purchased Volume (EUR) 
04- October -2021          20,000                 43.7493             874,986.00 
05- October -2021          40,000                 43.8333            1,753,332.00 
06- October -2021          19,926                 44.0809             878,356.01 
07- October -2021          35,000                 43.9647            1,538,764.50 
08- October -2021          32,000                 44.2552            1,416,166.40 
      Total                146,926                43.9786            6,461,604.91 

The underlying individual trades are published on the website of QIAGEN N.V. (https://corporate.qiagen.com/ investor-relations/stock-information/share-buyback/default.aspx).

The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from September 27, 2021 until and including October 8, 2021 amounts to 221,663 shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 12 October 2021

Managing Board

### Contacts:


Investor Relations                      Public Relations 
John Gilardi          +49 2103 29 11711 Dr. Thomas Theuringer +49 2103 29 11826 
e-mail: ir@qiagen.com                   e-mail: pr@qiagen.com 


2021-10-12 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language:     English 
Company:      QIAGEN N.V. 
              Hulsterweg 82 
              5912 PL Venlo 
Internet:     www.qiagen.com 
End of News   DGAP News Service 

1240108 2021-10-12

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1240108&application_name=news

(END) Dow Jones Newswires

October 12, 2021 08:15 ET (12:15 GMT)

All news about QIAGEN N.V.
12/02QIAGEN N.V. : Notification and public disclosure of transactions by persons
12/02QIAGEN Launches CE-marked Version of QuantiFERON« SARS-CoV-2 to Assess T-cell Response ..
12/01QIAGEN NV : Goldman Sachs reiterates its Neutral rating
11/29Qiagen's Tuberculosis Detection Test Gets FDA Approval for Use on DiaSorin's Liaison XS..
11/29QIAGEN N.V. : Notification and public disclosure of transactions by persons
11/29QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of ..
11/26Health Care Stocks Slip But Outperform Broader Friday Markets as COVID Worries Re-Emerg..
11/26Qiagen's COVID-19 PCR Tests Remain Accurate in Detecting South African Variant; Shares ..
11/26QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavi..
11/26QIAGEN N.V. Reaffirms Effectiveness of SARS-CoV-2 PCR Tests in Light of the New Coronav..
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2021 2 196 M - -
Net income 2021 475 M - -
Net Debt 2021 938 M - -
P/E ratio 2021 26,0x
Yield 2021 -
Capitalization 12 305 M 12 305 M -
EV / Sales 2021 6,03x
EV / Sales 2022 6,24x
Nbr of Employees 6 000
Free-Float 97,8%
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 54,20 $
Average target price 57,63 $
Spread / Average Target 6,32%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.2.57%12 305
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298